1-4 of 4
C. Mitsiades
Close
Sort by
Journal Articles

A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).

Paul Richardson, MD, Asher Alban Chanan-Khan, MD, Sagar Lonial, MD, Amrita Krishnan, MD, Melissa Alsina, MD, Michael Carroll, MD, Karen Adler, G. Cropp, C. Mitsiades, MD, Robert Johnson, MD, PhD, Alison Hannah, MBBS, Kenneth C. Anderson, MD
Journal: Blood
Blood (2006) 108 (11): 406.
https://doi.org/10.1182/blood.V108.11.406.406
Published: 2006
Journal Articles

A Phase 1 Trial of Lenalidomide (REVLIMID ® ) with Bortezomib (VELCADE ® ) in Relapsed and Refractory Multiple Myeloma.

Paul Richardson, R. Schlossman, N. Munshi, D. Avigan, S. Jagannath, M. Alsina, D. Doss, M. McKenney, K. Hande, M. Farrell, S. Gorelik, K. Colson, D. Warren, L. Lunde, R. Michelle, G. Cole, C. Mitsiades, T. Hideshima, T. Myers, R. Knight, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 365.
https://doi.org/10.1182/blood.V106.11.365.365
Published: 2005
Journal Articles

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. Cheng, S. Eschrich, B. Burrington, P. Richardson, W. Trepicchio, J. Shaughnessy, L. Bergsagel, A. Damokosh, A. Boral, D. Esseltine, D. Schenkein, K. Anderson
Journal: Blood
Blood (2005) 106 (11): 3491.
https://doi.org/10.1182/blood.V106.11.3491.3491
Published: 2005
Journal Articles

Phase 1 Clinical Trial of KOS-953 + Bortezomib (BZ) in Relapsed Refractory Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, P. G. Richardson, MD, M. Alsina, MD, M. Carroll, MD, S. Lonial, MD, A. Krishnan, MD, M. Albitar, MD, Y. Zhou, MD, C. Mitsiades, MD, G. Cropp, MS, A. L. Hannah, MD, K. C. Anderson, MD
Journal: Blood
Blood (2005) 106 (11): 362.
https://doi.org/10.1182/blood.V106.11.362.362
Published: 2005